Opinion|Videos|February 12, 2024
DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors
Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.
Advertisement
Episodes in this series
Advertisement
Related to this article
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
2
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
3
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5